Default Category
-
Telecommunications Regulation and Coordinated Competition in Romania
Daemmrich, Arthur A.; Radu, Alex; Sarbu, AnaCase HBS-713016-EEconomicsLeaders of the Romanian telecommunications agency must decide about a proposed international merger and how to structure bandwidth auctions critical to the telecoms market. The case is designed to teach about regulatory choices from the perspective of a regulatory agency, but it also describes the competitive standing of domestic and international telecoms providers in Romania and the challenges of operating as a "foreign" multinational, even in ...Starting at €8.20
-
International Lobbying and The Dow Chemical Company (B): Regulatory Reform in the USA
Daemmrich, Arthur A.Case HBS-710028-EEconomicsStarting at €5.74
-
International Lobbying and the Dow Chemical Company (PPT)
Daemmrich, Arthur A.Case HBS-711089-EEconomicsTo be used with cases 710027 and 710028.Starting at €8.20
-
U.S. Healthcare Reform: Reaction to the Patient Protection and Affordable Care Act of 2010
Daemmrich, Arthur A.Case HBS-711103-EEconomicsSupplement to "U.S. Healthcare Reform: International Perspectives," HBS No. 710-040, updating key events and disputes concerning the reform law, including the 2010 Congressional elections, legislative proposals, legal challenges, and responses by employers.Starting at €8.20
-
Denmark: Globalization and the Welfare State
Daemmrich, Arthur A.; Kramarz, BenjaminCase HBS-709015-EEconomicsThis case describes how Denmark has balanced the impacts of globalization, including outsourcing and movement of labor with its social welfare offerings. Reforms implemented during the past two decades drove down unemployment, promoted new company formation, and put the country at or near the top of international polls on the ease of doing business. The case describes how Danes forged a consensus that embraced international trade and outsourcing ...Starting at €8.20
-
A Managerial Perspective on Clinical Trials
Daemmrich, Arthur A.Case HBS-709033-EEntrepreneurshipThis note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70 percent of a drug's total development costs, pharmaceutical and biotechnology leaders need to understand clinical trial management. Likewise, with a growing variety of new product i...Starting at €8.20
-
Brazil: Leading the BRICs?
Daemmrich, Arthur A.; Musacchio, AldoCase HBS-711024-EEconomicsBrazil's new president, Dilma Rousseff, had announced plans to sustain GDP growth above 5 percent annually and continue the country's leadership role among emerging economies. Between 2003 and 2010, Brazil benefited from strong economic growth and stable policies under the Lula administration. Brazil also increasingly led the BRICs (the fast-growing countries of Brazil, Russia, India, and China) in multilateral negotiations, notably in the World ...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change (Abridged)
Daemmrich, Arthur A.Case HBS-711050-EArcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology company, notably uneven enforcement of intellectual property in emerging market countries, and uncertainty regarding the provision and market value of carbon credits under international c...Starting at €8.20
-
Denmark: Globalization and the Welfare State (PPT)
Daemmrich, Arthur A.Case HBS-711057-EEconomicsStarting at €8.20
-
Targanta Therapeutics: Hitting a Moving Target
Daemmrich, Arthur A.Case HBS-709002-EEntrepreneurshipThis case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta - which has just held a successful IPO - weighs options for the approximately ten month review period after the company submits to the Food and Drug Administration. The case reviews Targanta's origins and "de-riskin...Starting at €8.20